Objective-Low-density lipoprotein (LDL) cholesterol induces endothelial dysfunction and is a major modifiable risk factor for coronary heart disease. Endothelial Kruppel-like Factor 2 (KLF2) is a transcription factor that is vital to endotheliumdependent vascular homeostasis. The purpose of this study is to determine whether and how LDL affects endothelial KLF2 expression. Approach and Results-LDL downregulates KLF2 expression and promoter activity in endothelial cells. LDL-induced decrease in KLF2 parallels changes in endothelial KLF2 target genes thrombomodulin, endothelial NO synthase, and plasminogen activator inhibitor-1. Pharmacological inhibition of DNA methyltransferases or knockdown of DNA methyltransferase 1 prevents downregulation of endothelial KLF2 by LDL. LDL induces endothelial DNA methyltransferase 1 expression and DNA methyltransferase activity. LDL stimulates binding of the DNA methyl-CpG-binding protein-2 and histone methyltransferase enhancer of zeste homolog 2, whereas decreases binding of the KLF2 transcriptional activator myocyte enhancing factor-2, to the KLF2 promoter in endothelial cells. Knockdown of myocyte enhancing factor-2, or mutation of the myocyte enhancing factor-2 site in the KLF2 promoter, abrogates LDLinduced downregulation of endothelial KLF2 and thrombomodulin, and KLF2 promoter activity. Similarly, knockdown of enhancer of zeste homolog 2 negates LDL-induced downregulation of KLF2 and thrombomodulin in endothelial cells. Finally, overexpression of KLF2 rescues LDL-induced clotting of platelet-rich plasma on endothelial cells.
H ypercholesterolemia is associated with vascular endothelial dysfunction. 1 Elevation of low-density lipoprotein (LDL) cholesterol in subjects with hypercholesterolemia is a strong predictor of myocardial infarction and cardiovascular death, 2 and lowering of LDL cholesterol reduces this risk 3 and improves endothelial function. 4 LDL can be converted to oxidized LDL in the subendothelial space where its uptake by macrophages leads to the formation of foam cells, which play a central part in the formation of an atherosclerotic plaque. 5 In addition, both native and oxidized LDL promote endothelial dysfunction, resulting in a proinflammatory and proadhesive endothelial phenotype, thus perturbing endothelium-dependent vascular homeostasis.
Kruppel-like factors (KLFs) is a subclass of the zinc-finger family of transcription factors important in cell differentiation and growth. 6 KLF2 is highly expressed in vascular endothelium and orchestrates endothelium-dependent vascular homeostasis in health. 7, 8 KLF2 expression in the endothelium is upregulated by laminar shear stress and inhibited by proinflammatory cytokines. 9, 10 Endothelial KLF2 orchestrates vascular homeostasis through transcriptional regulation of several target genes, among which are endothelial NO synthase (eNOS) plasminogen activator inhibitor-1 (PAI-1) and thrombomodulin (TM). By upregulating or downregulating these genes, KLF2 fosters an anti-inflammatory and antithrombotic endothelial surface, and protects the endothelium from injury. 10 Mice lacking one allele of KLF2 are prone to atherosclerosis when challenged with a high-fat diet, 11 underscoring the important atheroprotective role of KLF2.
Transcription of KLF2 is largely governed by its proximal promoter, which is highly conserved between mouse and human. [12] [13] [14] This region of the promoter is abundant in CpG dinucleotides, and also has within it the major regulatory elements governing KLF2 expression, including a binding site for myocyte enhancing factor-2 (MEF2), a transcription factor which upregulates KLF2, 9, 10, 15 and the tumor suppressing transcription factor p53 which downregulates KLF2. 16 Although studies on epigenetic modulation of KLF2 expression are limited, emerging evidence suggests that histone modifiers, such as the histone methyltransferase enhancer of zeste homolog 2 (EZH2), the catalytic subunit of Polycomb repressive complex 2 which is implicated in tumorigenesis and is responsible for trimethylation of Histone 3 on lysine 27, play an important part in governing KLF2 expression. 17 Cholesterol-rich lipid particles and hypercholesterolemia are associated with epigenetic changes in vitro and in experimental animal models as well as in humans. ApoE −/− mice fed a high-fat diet have aberrant DNA methylation patterns, including decreased global methylation in aorta and peripheral blood mononuclear cells, 18 and human atherosclerotic tissue samples display genomic hypomethylation. 19 P66shc is one of the genes epigenetically modified by cholesterolrich proatherogenic particles, such as LDL. 20 P66shc mediates endothelial oxidative stress and fatty streak formation in hypercholesterolemic mice. 21 However, p66shc is only one of many genes whose epigenetic modification by hypercholesterolemia may contribute to the development of vascular disease. Intrigued by the possibility that endothelial KLF2 might also be epigenetically regulated in a hypercholesterolemic environment, we asked whether LDL cholesterol changes endothelial KLF2 transcription, and investigated the roles of DNA and histone-modifying enzymes in such changes.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

LDL Represses Endothelial KLF2 Expression and Modulates KLF2-Dependent Gene Expression
We first determined whether LDL affects endothelial KLF2 expression. In human umbilical vein endothelial cells (HUVEC), LDL suppresses KLF2 expression at the RNA and protein levels ( Figure 1A and 1B). To determine whether downregulation of KLF2 occurs via a transcriptional mechanism, we examined the effect of LDL on KLF2 promoter activity. In HUVEC, LDL represses KLF2 promoter activity ( Figure 1C ). Importantly, the region 200-bp upstream of the ATG (initiation codon) site is sufficient to confer this effect ( Figure 1C ), indicating that the LDL-responsive element is within this proximal part of the promoter.
Previous work has demonstrated the important role of p53 in repressing KLF2 transcription. 16 Therefore, we investigated the role of p53 in LDL-induced suppression of KLF2 transcription. LDL downregulates KLF2 at the mRNA and protein levels equally in p53-positive and p53-negative colon cancer HCT116 cell lines ( Figure IA and IB in the online-only Data Supplement), indicating no role for p53 in LDL-induced KLF2 repression. Moreover, mutation of the p53-response element does not affect downregulation of KLF2 promoter activity by LDL ( Figure IC in the online-only Data Supplement). Because p66shc, an adaptor protein that promotes oxidative stress and whose expression is upregulated by LDL, 20 also governs endothelial KLF2, 22 we further asked whether p66shc plays any role in LDL-stimulated downregulation of KLF2. Knockdown of p66shc in endothelial cells does not interfere with LDL-stimulated repression of KLF2 ( Figure II in the online-only Data Supplement), indicating that LDL does not require p66shc to inhibit KLF2 expression. Importantly, small interfering RNA-mediated knockdown of the endothelial LDL receptor does abrogate LDL-stimulated downregulation of KLF2 ( Figure III in the online-only Data Supplement), indicating that the signal transduction pathway for transcriptional repression involves the classic receptor-ligand interaction.
Next, we determined whether downregulation of KLF2 is associated with changes in expression of its target genes. TM and eNOS, which are upregulated by KLF2 and suppress vascular inflammation and thrombosis, are downregulated by LDL, whereas expression of PAI-1, which is repressed by KLF2 and promotes thrombosis, is increased by LDL ( Figure 1B ). Taken together, these findings show that LDL transcriptionally downregulate endothelial KLF2 and impact on KLF2-mediated endothelial gene expression.
LDL Downregulates Endothelial KLF2 Expression via DNA Methylation
To address the role of epigenetic modifications in KLF2 downregulation by LDL, we first asked whether DNA methyltransferases (DNMT) mediate the effect of LDL. In HUVEC, in which global DNMT activity was inhibited with 5-aza-2′deoxycytidine (5-aza-2′-dC), LDL fails to downregulate KLF2 and TM (Figure 2A and 2B). To dissect the role of specific DNMTs, we then targeted DNMT1, which is responsible for de novo DNA methylation in postnatal tissues. Knockdown of DNMT1 in HUVEC ( Figure IVA in the online-only Data Supplement) increases basal expression of KLF2 and also prevents downregulation of KLF2 by LDL ( Figure 2C and 2D).
In addition, endothelial DNMT1 expression, and total DNMT activity, is significantly increased by LDL ( Figure 2E and 2F). Thus, LDL downregulates KLF2 via induction of DNMT1. Additionally, we directly assessed the effect of methylation of CpG dinucleotides on KLF2 promoter activity. In vitro methylation of CpG dinucleotides in the KLF2 promoterreporter construct with the Sss1 methyltransferase results in marked suppression of promoter activity ( Figure 2G ), providing further proof for the role of CpG methylation in regulation of KLF2 transcription. Moreover, we also examined the role of DNA methylation in regulating KLF2 expression in 2 tumor cell lines: the MDA-MB-435 breast cancer line, and the Jurkat T-cell leukemia line. KLF2 expression is silenced or minimal in both these cell lines. Treatment of MDA-MB-435 or Jurkat T-cells with 5-aza-2′-dC robustly upregulates KLF2 ( Figure VA and VB in the online-only Data Supplement), suggesting that regulation of KLF2 expression by DNA methylation is not unique to endothelial cells.
LDL Increases Occupancy of the KLF2 Promoter by MeCP2 and EZH2, and Decreases Occupancy of the Promoter by MEF2
Methylated CpG dinucleotides form a template on which assemble a complex of transcriptional repressors, among which is methyl-CpG-binding protein-2 (MeCP2). MeCP2 binds to methylated CpG dinucleotides that are often in proximity to an AT-rich DNA sequence. Within the proximal KLF2 promoter is a putative MeCP2-binding site, which fits these parameters and is highly conserved ( Figure 3A ). Therefore, we asked whether LDL stimulates binding of MeCP2 to this region of the KLF2 promoter. Chromatin immunoprecipitation assays revealed that LDL promotes binding of MeCP2 to this portion of the KLF2 promoter ( Figure 3B ). Thus, LDL stimulates binding of MeCP2, an epigenetic repressor, to the KLF2 promoter.
Histone methyltransferases are a class of histone-modifying enzymes that can also be recruited to the transcriptional repressor complex at gene promoters. The histone methyltransferase EZH2 represses KLF2 expression in cancer cells. 17 KLF2 downregulation. We first asked whether LDL leads to recruitment of EZH2 to the KLF2 promoter. Chromatin immunoprecipitation assays showed that LDL increases occupancy of the KLF2 promoter by EZH2 ( Figure 3C ). Because histone deacetylases (HDACs) are another class of histone-modifying enzymes involved in gene repression, we also asked whether they participate in LDL-stimulated suppression of endothelial KLF2. Chromatin immunoprecipitation assays showed that LDL does not stimulate deacetylation of Histone 3, a signature mark of chromatin silencing mediated by HDACs, on the KLF2 promoter ( Figure VIA in the online-only Data Supplement). Together, these findings indicate that EZH2, but not HDACs, forms part of the repressor complex assembled at the proximal KLF2 promoter in endothelial cells exposed to LDL.
The KLF2 promoter has the highly conserved site for the MEF2 transcription factor that upregulates its expression. Therefore, we next examined the effect of LDL on occupancy of the KLF2 promoter by MEF2. Chromatin immunoprecipitation assays showed that in contrast to MeCP2 and EZH2, LDL decreases occupancy of the KLF2 promoter by MEF2 ( Figure 3D ). Thus, LDL leads to a shift in KLF2 promoter occupancy from the transcriptional activator MEF2, to a transcriptional repressor complex consisting of MeCP2 and EZH2.
MEF2 and EZH2 Are Essential for LDL-Induced Downregulation of KLF2
Next, we addressed the role MEF2 and EZH2 play in downregulation of KLF2 by LDL. First, MEF2 expression was knocked down in endothelial cells with small interfering RNA ( Figure IVB in the online-only Data Supplement; Figure 4B ). Knockdown of MEF2 leads to downregulation of basal endothelial KLF2, but more importantly, negates LDL-induced repression of KLF2, both at the mRNA and protein levels ( Figure 4A and 4B) . Moreover, TM downregulation by LDL is similarly dependent on MEF2 ( Figure 4B ). In addition, mutation of the MEF2 response element in the KLF2 promoter ( Figure 3A) abrogates LDL-induced decrease in promoter activity ( Figure 4C ). LDL, however, does not downregulate endothelial MEF2 ( Figure 4B ; Figure IVB in the online-only Data Supplement). These findings highlight that MEF2 is essential for LDL-stimulated downregulation of endothelial KLF2 and, together with the finding that LDL decreases MEF2 occupancy of the KLF2 promoter, indicate that decrease in MEF2-mediated KLF2 transcription plays a vital role in suppression of endothelial KLF2 by LDL. Second, we knocked down EZH2 expression in endothelial cells ( Figure IVC Figure 4E) . In contrast to knockdown of EZH2, Trichostatin A, a pan-HDAC inhibitor, does not prevent decrease in KLF2 induced by LDL ( Figure VIB in the online-only Data Supplement). Thus, EZH2 is essential for downregulation of endothelial KLF2 by LDL, whereas HDACs are not.
Overexpression of KLF2 Rescues Endothelial Cells From a Procoagulant Phenotype Induced by LDL
Upregulation of TM and eNOS, and downregulation of PAI-1 are some of the transcriptional mechanisms by which KLF2 mediates an anti-inflammatory and antithrombotic endothelial surface. Therefore, we asked whether LDL stimulates a procoagulant endothelium and whether downregulation of KLF2 is responsible for this phenotype. Exposure of endothelial cells to LDL decreased time to clotting of plasma on their surface (Figure 5 ), signifying a shift toward a procoagulant phenotype. This hypercoagulability was rescued by adenoviral overexpression of KLF2 ( Figure 5 ), indicating that downregulation of KLF2 plays an important part in LDLinduced coagulation of platelet-rich plasma on the endothelial cell surface. 
Discussion
KLF2 transcription is regulated by several stimuli (eg, laminar and nonlaminar shear stress, inflammatory cytokines) present in health or disease, via interaction of various transcriptional activators and repressors at the KLF2 promoter. The promoter is guanine-cytocine rich, and has a CpG island within it. Many CpG dinucleotides in this island are conserved among different species ( Figure 3A) . This reinforces the concept that CpG hypermethylation contributes to transcriptional regulation of KLF2 expression. Out data suggest that LDL, by inducing DNMT1, recruits a transcriptional repressor complex consisting of MeCP2 and EZH2 to the KLF2 promoter, at the expense of occupancy of the promoter by MEF2. This shift in promoter occupancy results in a transcriptionally closed chromatin and silencing of KLF2 expression ( Figure 6 ). It is worthwhile noting that the putative binding site for MeCP2 and the known binding site for MEF2 in the KLF2 promoter are adjacent to each other and may overlap ( Figure 3A) , raising the possibility that MeCP2 and MEF2 compete for promoter occupancy.
It is well recognized that changes in CpG methylation occur during the pathogenesis of atherosclerosis. However, whether CpG hypermethylation or hypomethylation plays a causative role in this process remains controversial. Newman 23 first suggested that reduced global DNA methylation pattern increases the atheromatous process, linking it to the inadequate production of S-adenosylmethionine in serum. Similarly, in a mouse model of hypercholesterolemia, atherogenic lipoproteins result in an aberrant DNA methylation pattern. 18 These mice have decreased DNA methylation in the aorta and in circulating inflammatory cells that are directly involved in progression or initiation of atherosclerosis. 18 Supporting a role for CpG hypomethylation of specific genes in relevant cardiovascular cell types in promoting atherogenesis, LDL cholesterol hypomethylates the promoter of p66shc in endothelial cells, 20 a gene that promotes oxidative stress and plays an important part in endothelial dysfunction of aging, 24 diabetes mellitus, 25 and hypercholesterolemia. 21 On the contrary, there are also many examples where LDL cholesterol hypermethylates vasoprotective genes. For example, oxidized LDL inhibits the expression of its own receptor, LOX1, in endothelial cells via hypermethylation of the LOX1 promoter. 26 Moreover, some reports have shown hypermethylation of estrogen receptor-α and β in human atherosclerotic lesions. 27 Therefore, both hypermethylation and hypomethylation of targeted genes in vascular cells may contribute to development and progression of atherosclerotic disease triggered by hypercholesterolemic states. Among the mammalian DNMTs, DNMT1 maintains CpG methylation in postnatal tissues, whereas DNMT3 (DNMT3a and DNMT3b) is responsible for de novo methylation and is the principal methyltransferase that contributes to a wave of methylation that occurs during embryogenesis. 28 DNA methylation represses gene expression partly by recruitment of MeCP2, which selectively interacts with methylated CpG dinucleotides. 29 MeCP2 recruits HDACs to the chromatin, 30 or may repress gene expression by chromatin condensation independent of histone deacetylation. 31 With regard to the latter, MeCP2 can recruit histone methyltransferases, such as EZH2, which methylates histones to alter gene expression. 32 Our findings indicate that KLF2 repression by LDL is mediated by EZH2, but not by HDACs, and is consistent with the role of EZH2 in silencing KLF2 expression in tumor cells. 17 Although our results show that downregulation of KLF2 contributes to endothelial activation triggered by LDL cholesterol, it is possible that expression of other endothelial KLFs is similarly impacted through epigenetic mechanisms by LDL and hypercholesterolemia. KLF4 is well expressed in endothelial cells and shares many of its target genes with KLF2, such as eNOS, TM, and PAI-1. 33 Interestingly, there is loss of physiological KLF4 expression in medulloblastomas and T-cell leukemias, the KLF4 gene is hypermethylated on histones and CpG dinucleotides in these tumors, and inhibition of DNMTs increases KLF4 expression. 34, 35 Although our studies were limited to endothelial cells, KLF2 is expressed in circulating leukocytes, which can acquire an inflammatory phenotype under hypercholesterolemic conditions. Monocytes are transformed to macrophages, which play a vital role in vascular inflammation associated with atherosclerosis. Notably, expression of KLF2 in peripheral blood monocytes inversely correlates with the extent of atherosclerotic disease, 36 and oxidized LDL inhibits KLF2 expression in macrophages, 37 suggesting that epigenetic silencing of KLF2 in monocytes and macrophages may contribute to a proinflammatory phenotype acquired in hypercholesterolemic conditions. We similarly observed that oxidized LDL downregulates KLF2 expression in endothelial cells ( Figure   VII in the online-only Data Supplement), but did not probe the molecular mechanisms responsible for this downregulation. It is noteworthy that DNMTs are impacted by the oxidative milieu, 38 and that oxidized LDL could, thus, affect gene expression via oxidative stress. However, oxidative stress is unlikely to be responsible for the effect of native LDL because p66shc, a master regulator of the cellular redox environment, does not mediate LDL-induced repression of KLF2 ( Figure II in the online-only Data Supplement).
In conclusion, our findings provide new molecular insights into how LDL cholesterol may increase the risk of atherosclerotic heart disease. They show that one of the pathways through which LDL leads to endothelial activation and dysfunction is via epigenetic downregulation of KLF2. Therefore, targeted inhibition of DNA and histone methylation, if achievable, could provide a new therapeutic approach to combating hypercholesterolemia-associated vascular dysfunction and disease. Figure 6 . Schematic of proposed mechanism by which low-density lipoprotein (LDL) downregulates endothelial Kruppel-like Factor 2 (KLF2) leading to impaired endothelial function. LDL or hypercholesterolemia-stimulated DNA methyltransferase 1 (DNMT1)-mediated CpG methylation of the KLF2 promoter leads to recruitment of methyl-CpG-binding protein-2 (MeCP2) and enhancer of zeste homolog 2 (EZH2), promoting histone methylation and transcriptional silencing of endothelial KLF2. eNOS indicates endothelial NO synthase; PAI-1, plasminogen activator inhibitor-1; and TM, thrombomodulin.
